Lawmakers grilled FDA Commissioner Marty Makary on a variety of issues during a Senate budget hearing, including the agency’s new Covid-19 vaccine framework, the accidental firings of infant formula scientists, and the pace of regulatory approval for rare disease drugs. Makary faced frustration from lawmakers as he refuted reports of slow-downs at the agency and disagreed with them over his and health secretary Robert F. Kennedy Jr.’s past statements that layoffs did not impact scientists.
The hearing, originally intended to focus on the Trump administrationâs 2026 budget request, delved into numerous FDA issues that are currently in the political spotlight. Despite the lack of mention of the FDA’s budget in the presidentâs preliminary spending package, Makary highlighted in his opening remarks that the agency is requesting $6.8 billion for the upcoming year, with $3.6 billion coming from industry user fees.
However, the discussion took a turn as the hearing was abruptly interrupted by a restricted content message, indicating that the article was exclusive to STAT+ subscribers. The message urged readers to subscribe to access the full story, along with daily intelligence on Capitol Hill and the life sciences industry.
The restricted content message left many readers frustrated as they were unable to continue reading the detailed account of the Senate budget hearing with FDA Commissioner Marty Makary. The article’s abrupt interruption highlighted the challenges of accessing vital information in today’s digital landscape, where exclusive content is often reserved for paid subscribers.
Overall, the Senate budget hearing with FDA Commissioner Marty Makary shed light on crucial FDA issues, but the restricted content message served as a reminder of the growing divide between free and paid access to information in the media industry.
